2025 – Page 9 – Talk Bio

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

2 weeks ago talkbio0Tagged amgen, Approved, Biological Factors, Biosimilars, competition, Enbrel, Erelzi, etanercept, Legal patent, Market, Rheumatoid Arthritis, sandoz, United States, United States Food and Drug Administration

Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.

PRISM BioLab and Elix Collaborate to Revolutionize AI-Driven Drug Discovery with Peptide Mimetics

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Drug Discovery, Efficiency, Elix, mimetics, PepMetics, Peptides, pharmaceutical innovation, PRISM BioLab, Protein-Protein Interaction, small molecule inhibitors

PRISM BioLab , Elix , AI drug discovery , Peptide mimetics , Protein-protein interactions , PepMetics® , Small molecule inhibitors , Drug discovery efficiency , Pharmaceutical innovation

FDA Union Prepares for Negotiations as HHS Job Cuts Reshape Workforce

2 weeks ago talkbio0Tagged Advocacy, CHARGE Syndrome, employee layoffs, federal, Force, layoffs, Mediation, public health medicine (field), reduction in force, restructuring, Union, United States Food and Drug Administration

FDA layoffs, HHS restructuring, Union negotiations, Reduction in Force (RIF), Robert F. Kennedy Jr., FDA workforce reduction, HHS employee layoffs, Federal health agencies, Public health impact, Union advocacy

Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment

2 weeks ago talkbio0Tagged Danuglipron, GLP-1 receptor, GLP-1/GIP therapies, Injury of liver, Metabolic Diseases, Obesity, Pfizer, Pharmaceutical competition, pipeline, Weight-Loss Agents

Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline

Verve’s 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision

2 weeks ago talkbio0Tagged Safety, VERVE-102

VERVE-102, Safety

Amgen Secures Phase 3 Survival Data for Imdelltra in Small-Cell Lung Cancer, Strengthening Its Case for Full FDA Approval

2 weeks ago talkbio0Tagged amgen, Biological Factors, DLL3-targeting therapy, Imdelltra, Immunotherapy, Overall Survival, Phase 3 trial, SCLC, small-cell lung cancer

Imdelltra, Amgen, Small-cell lung cancer (SCLC), Phase 3 trial, Overall survival, DLL3-targeting therapy, Immunotherapy, Biopharmaceuticals

Biopharma Layoff Trends in Q1 2025 and Outlook for Q2

2 weeks ago talkbio0Tagged Biopharma, Biopharma layoffs, Changing, Industry, Legal patent, Pharma, pharmaceutical employment, Q1 2025, Q2 layoff, regulatory, restructuring

Biopharma layoffs, Q1 2025 layoffs, biotech job cuts, pharma workforce reductions, restructuring, patent cliffs, regulatory challenges, Q2 layoff forecast, pharmaceutical employment trends, biopharma industry changes.

As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay

2 weeks ago talkbio0Tagged alternatives, Clinical Trials, gene therapy, Hemgenix, HYMPAVZI, Pfizer, SMPX gene

Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials

Tome Bio founders wrangle jumping genes to create new programmable gene insertion tool

2 weeks ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, PGI, Retrotransposons, Technology

PGI, Technology, Retrotransposons, Clustered Regularly Interspaced Short Palindromic Repeats

Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges

3 weeks ago talkbio0Tagged biotech, Clinical Trial Failures, Cost savings programs, Glycogen storage disease type II, Industry, Opthea layoffs, Pfizer, Pfizer staff, Pharma, restructuring

Opthea layoffs 2025 , Pfizer staff reduction , Biotech job cuts , Pharma restructuring , Clinical trial failures , Wet AMD treatment , Cost savings programs , Pfizer San Diego layoffs , Biotech industry challenges